Earlier signal means a longer window to act, and a more confident conversation with the patient about what comes next. It is the difference between seeing a relapse three months before imaging does, or three months after the patient does.
This is the foundational claim under everything else. Without the sensitivity, the lead time does not exist.

No transatlantic shipping, no currency friction, no patient data crossing into a different regulatory regime. For a European private clinic, that removes the operational and compliance headache that comes with most ctDNA options.

Personal blood and tissue collection kits make sample collection straightforward at the point of care.

The report is a clinical view of what is happening in that patient's tumour, not a binary flag. For a premium monitoring offer, that is the level of insight that justifies the service and supports the next treatment decision.

If the question is whether there is residual disease, we answer it. If the question is what the tumour is doing now, the platform was built for that one.

When you sit across from a patient, you can explain why the result says what it says. When a referring oncologist asks how the call was made, there is an answer beyond a number. That is what makes a monitoring result usable in a real clinical conversation.

Transparency is not just for researchers. It is what lets a clinician trust the result enough to act on it.

When you need a second set of eyes on an unexpected result, you get one, from someone who has seen results like it before. Onboarding help to set the service up in your clinic, and ongoing support once it is running.

We are not the right partner for every clinic. We are an exceptionally good partner for the ones we are right for